Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Trounced the Market on Thursday

By Eric Volkman - Mar 11, 2021 at 5:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There was some excellent news about the company's most famous product.

What happened

BioNTech (BNTX 0.53%), which shot to fame as the co-developer of the BNT162b2 vaccine with Pfizer (PFE -0.93%), well outpaced the 1% gain of the S&P 500 index on Thursday, closing the trading session nearly 5% higher. One big piece of news about its COVID-19 vaccine was particularly encouraging.

So what

The driver of Thursday's share price move was an announcement from BioNTech, Pfizer, and Israel's Ministry of Health drawing on data from the country's vaccination program. According to a comprehensive study, BNT162b2's "effectiveness was at least 97% in preventing symptomatic disease, severe/critical disease and death."

Gloved hand filling a syringe from a vial.

Image source: Getty Images.

Crucially, during the seven weeks for which the data was being collected (Jan. 17 to March 6), BNT162b2 was the only vaccine authorized for use in Israel, and the so-called U.K. variant was the dominant strain of the coronavirus there. Health officials have expressed concern about that variant, as it appears to be significantly more transmissible than the original strain.

There was further good news on the asymptomatic infection front. The analysis conducted by the two companies and the Health Ministry found that BNT162b2 was 94% effective at preventing such infections.

"This clearly demonstrates the power of the COVID-19 vaccine to fight this virus and encourages us to continue even more intensively with our vaccination campaign," said Dr. Yeheskel Levy, director of the Ministry of Health.

Now what

These findings are excellent for the vaccine's makers, although curiously, Pfizer shares actually dipped Thursday. The difference might be that the near-term fortunes of BioNTech, a relatively small biotech, are far more dependent on BNT162b2 than are those of its giant partner.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
$158.84 (0.53%) $0.84
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.92 (-0.93%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.